SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Posted inDiabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermediate baseline fibrosis.
Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoints are needed to establish meaningful benefit.
Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
Posted inDiabetes & Endocrinology Gastroenterology news

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver health, glycemic control, and lipid profiles, underscoring potential dietary strategies for MASLD management.
Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score
Posted inGastroenterology news Oncology

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score

Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful monitoring despite low PAGE-B scores.
Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timing or late time-restricted feeding.